|
| 36400666 | Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis. | Urol Oncol | 2023 |
| 37218065 | Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen. | Br J Haematol | 2023 |
| 37236698 | Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis. | Lancet Digit Health | 2023 |
| 34716049 | Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. | Eur Urol | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 36470901 | Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. | Nat Commun | 2022 |
| 36315915 | APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. | JCO Precis Oncol | 2022 |
| 36063163 | Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). | Genet Med | 2022 |
| 35101336 | Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). | Genet Med | 2022 |
| 35176763 | The Genomics of Colorectal Cancer in Populations with African and European Ancestry. | Cancer Discov | 2022 |
| 35050711 | <i>ERBB2</i> Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. | JCO Precis Oncol | 2022 |
| 34753780 | The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. | Clin Cancer Res | 2022 |
| 32884129 | A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. | Mod Pathol | 2021 |
| 33512481 | Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. | Blood | 2021 |
| 33558422 | Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. | Clin Cancer Res | 2021 |
| 33687775 | Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. | Oncologist | 2021 |
| 34379803 | Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. | Cancer | 2021 |
| 34463133 | Real-world association of HER2/<i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. | Future Oncol | 2021 |
| 34626187 | Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12â¿¿139 Cancer Patients. | Clin Chem | 2021 |
| 34476332 | Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. | JCO Precis Oncol | 2021 |
| 34272304 | Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma. | J Immunother Cancer | 2021 |
| 34215504 | Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. | Urol Oncol | 2021 |
| 34242968 | Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. | ESMO Open | 2021 |
| 34313135 | Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing. | Future Oncol | 2021 |
| 34257540 | Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. | Pathol Oncol Res | 2021 |
| 33465286 | RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. | Oncologist | 2021 |
| 33336398 | Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases. | Int J Cancer | 2021 |
| 33077920 | Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. | Mod Pathol | 2021 |
| 33325309 | Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma. | Leuk Lymphoma | 2021 |
| 32368168 | Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors. | Lung Cancer (Auckl) | 2020 |
| 33192972 | Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. | Front Neurol | 2020 |
| 32744335 | Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics. | Clin Pharmacol Ther | 2020 |
| 32823229 | Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. | Lung Cancer | 2020 |
| 33015533 | <i>CDKN2C</i>-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of <i>TP53</i>/<i>RB1</i>-Wild-Type Tumor With Frequent <i>CIC</i> Genomic Alterations and 1p/19q-Codeletion. | JCO Precis Oncol | 2020 |
| 32923875 | Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. | JCO Precis Oncol | 2020 |
| 32123303 | Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. | Mod Pathol | 2020 |
| 32405805 | Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. | Acta Neuropathol | 2020 |
| 32483240 | Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. | Mod Pathol | 2020 |
| 31053601 | Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. | Clin Cancer Res | 2019 |
| 30770362 | PD-L1 and tumor-associated macrophages in de novo DLBCL. | Blood Adv | 2019 |
| 29936139 | Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. | EBioMedicine | 2018 |
| 27746218 | Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. | Biol Blood Marrow Transplant | 2017 |
| 28414090 | Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. | Hum Pathol | 2017 |
| 28375571 | HLA Mismatching Favoring Host-Versus-Graft NK Cell Activity Via KIR3DL1 Is Associated With Improved Outcomes Following Lung Transplantation. | Am J Transplant | 2017 |
| 29296835 | Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. | Blood Adv | 2017 |
| 28515356 | Licensing delineates helper and effector NK cell subsets during viral infection. | JCI Insight | 2017 |
| 25243620 | Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. | Bone Marrow Transplant | 2015 |
| 25810393 | KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia. | J Immunol | 2015 |
| 25776193 | A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. | Clin Lymphoma Myeloma Leuk | 2015 |
| 24958280 | CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. | Cancer Immunol Res | 2014 |